| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
105.67(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
90,386 |
178,372 |
278,007 |
460,221 |
| Total Sell Value |
$418,207 |
$740,302 |
$990,019 |
$3,011,511 |
| Total People Sold |
7 |
7 |
8 |
10 |
| Total Sell Transactions |
8 |
20 |
26 |
43 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Velleca Mark A. |
President and CEO |
• • – |
2017-12-18 |
4 |
OE |
$3.72 |
$27,900 |
D/D |
7,500 |
7,500 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-12-15 |
4 |
S |
$19.75 |
$3,950,000 |
D/D |
(200,000) |
2,950,630 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-12-01 |
4 |
S |
$19.75 |
$2,644,644 |
D/D |
(133,906) |
3,150,630 |
|
- |
|
| Shaffer Christy L |
Director |
– • – |
2017-11-30 |
4 |
A |
$0.00 |
$0 |
I/I |
995 |
995 |
|
- |
|
| Shaffer Christy L |
Director |
– • – |
2017-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(99,513) |
0 |
|
- |
|
| Reed Douglas Md |
10% Owner |
– – • |
2017-11-30 |
4 |
A |
$0.00 |
$0 |
I/I |
995 |
4,075,211 |
|
- |
|
| Reed Douglas Md |
10% Owner |
– – • |
2017-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(99,513) |
4,074,216 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-11-20 |
4 |
S |
$20.01 |
$4,002,000 |
D/D |
(200,000) |
3,284,536 |
|
- |
|
| Eshelman Fredric N |
Director |
– • • |
2017-11-13 |
4 |
B |
$19.73 |
$4,932,500 |
D/D |
250,000 |
250,000 |
3.92 |
- |
|
| Kolchinsky Peter |
Fmr 10% Owner See Footnote (2) |
– – – |
2017-05-22 |
4 |
B |
$15.00 |
$6,000,000 |
I/I |
400,000 |
2,684,244 |
0.01 |
- |
|
| Kolchinsky Peter |
Fmr 10% Owner See Footnote (2) |
– – – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,284,244 |
2,284,244 |
|
- |
|
| Eshelman Ventures, Llc |
10% Owner |
– – • |
2017-05-22 |
4 |
B |
$15.00 |
$4,500,000 |
D/D |
300,000 |
3,439,151 |
2.45 |
- |
|
| Eshelman Ventures, Llc |
10% Owner |
– – • |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,139,151 |
3,139,151 |
|
- |
|
| Reed Douglas Md |
10% Owner |
– – • |
2017-05-22 |
4 |
B |
$15.00 |
$1,999,995 |
I/I |
133,333 |
3,861,797 |
1.5 |
- |
|
| Reed Douglas Md |
10% Owner |
– – • |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
4,040,396 |
99,513 |
|
- |
|
| Eshelman Fredric N |
Director |
– • • |
2017-05-22 |
4 |
B |
$15.00 |
$4,500,000 |
I/I |
300,000 |
3,439,151 |
2.25 |
- |
|
| Eshelman Fredric N |
Director |
– • • |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
3,139,151 |
3,139,151 |
|
- |
|
| Shaffer Christy L |
Director |
– • – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
99,513 |
99,513 |
|
- |
|
| Strum Jay |
Chief Scientific Officer |
• – – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,666 |
58,569 |
|
- |
|
| Rudnick Seth |
Director |
– • – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,757 |
58,282 |
|
- |
|
| Muir Glenn P |
Director |
– • – |
2017-05-22 |
4 |
B |
$15.00 |
$300,000 |
D/D |
20,000 |
120,969 |
2.39 |
- |
|
| Muir Glenn P |
Director |
– • – |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
100,969 |
100,969 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-05-22 |
4 |
B |
$15.00 |
$1,125,000 |
D/D |
75,000 |
3,484,536 |
2.45 |
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,409,536 |
3,409,536 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2017-05-17 |
4/A |
B |
$15.00 |
$1,125,000 |
D/D |
75,000 |
3,409,536 |
2.45 |
- |
|
328 Records found
|
|
Page 13 of 14 |
|
|
0.21 (7.02%) 
